Paramount BioSciences, LLC (“Paramount”) is known as a top pharmaceutical drug development and investment organization having its principal concentration on the biotechnology and life sciences sectors. By using Paramount BioCapital, Inc., a FINRA listed broker-dealer in head of initial funding and raising capital for Portfolio firms, Paramount BioSciences intensely contributes to the emergence and development of modern biotechnologies and life sciences.

Paramount BioScienses’ Structure

Not only does Paramount BioSciences provide specialized services and assistance, but is also engaged in new product enhancement, biotech companies purchase and advancement. It helps the newly created businesses in a number of value-adding methods. They assess solution prospects for the organizations; produce growth plans to facilitate the creation process ahead of, during, as well as following the creation of Portfolio Firms. Equally, back-up and expertise is thoroughly supported by BioSciences as it permits its Portfolio Corporations to access to a lot more knowledgeable infrastructure than they may have. This allows the corporation administration to pay attention to the medicine candidates’ growth as opposed to building their unique infrastructure. In lots of ways, this model developed by Paramount’s originator Lindsay Rosenwald gives both expert and “back office” support and limits delays in the creation procedure, as well as maximized the earnings for Portfolio companies and the customer group.

Following acceptance and in-licensing, a devoted administration team throughout the full development cycle generally works on drug candidates. Senior medicine development employees at Paramount BioSciences, including Lindsay Rosenwald, help Portfolio Organizations in most aspects of pharmaceutical drug creation. This includes formulation, medical development, toxicology, production, quality assurance, and commercialization. Because of their extensive working experience in creating top prescription products, the Paramount’s staff gives options for a selection of therapeutically clues, starting from inflammation to cardiovascular system to oncology to neurology and several other signs. Worldwide network of experts in addition to business frontrunners in the medical and research communities provide guidance throughout the candidates’ growth and approval cycle.

Along with an established track record, Paramount BioSciences assists Portfolio Corporations recruit employees that will guide the fresh corporations created around the new compounds. One of several recent hires at Portfolio Organizations, you can find such executives as the past CEOs of Roche, Biogen, Sanofi-Aventis, Johnson&Johnson, Amgen and many more.

More than 20 years of financing and progression of biomedical firms throughout a wide range of therapeutic signs, Lindsay Rosenwald is head of Paramount BioSciences' more than 40 biotech firms. He forms firms from the nothing making use of his own capital after which funds are raised through various confidential individuals through Paramount Capital.

Paramount handles such critical capabilities as accounting, legal, market analytical, financial capabilities. This assists its Portfolio firms to focus on medical studies and generating value for shareholders, licensors and patients.

With such a keen eye for locating and constructing modern drug treatments, Paramount BioSciences raises the standard and promises of drug candidates across the world, from tiny biotech organizations and educational centres to big pharmaceutical businesses.

Paramount Approach To Value Generation

Exactly what tends to make Paramount BioSciences get noticed is that their structure and external network allows them to support Paramount Incubated Firms until finally they become self-sufficient. The production routine has been developed by Lindsay Rosenwald in 1998 and can be referred to in a simple scheme similar to this one:

Product Property --> Paramount Preliminary Funding and Expansion --> Incubation --> Portfolio Company Formation --> Cost Inflection Stage

Workers for each Portfolio Corporation are hired in compliance with developmental and fiscal circumstances. Typically, the majority of staff at Paramount currently has a minimum of 15 years of practical experience in biotechnology or health care sectors maneuvering drug prospects throughout the regulatory and clinical value cycle. Their expertise runs from molecular biology to clinical medicine.

With this kind of strong expertise through the drug development business, Lindsay Rosenwald has been able to produce the staff with leadership roles within the biotech market with numerous pharmaceutical products being sold globally, including Viracept, Neulasta, Rituxan, and Kepivance.

Paramount Sections

Paramount Biosciences

With around forty five staff members in 8 offices internationally, Paramount BioSciences contend and negotiate for higher education and business biotechnology entitlements. It develops and in-licenses materials for various restorative signs - from inflammation and cardiology to neurology and cancer. Lindsay Rosenwald helps construct standalone biotech firms, which could attract capital and succeed as publicly traded corporations

Paramount BioCapital, Inc.

Paramount BioCapital Inc. is a NASD-registered dealer that solicits money for the Portfolio Organizations. It brought in above $1 billion and around $200 million in 2009. With their extensive know-how in securities purchases such as “PIPEs”, reverse takeovers, self-registrations and private placements, Paramount BioCapital has become the leader inside the biotechnology capital market.

Paramount Improvement

Lindsay Rosenwald works closely with Paramount Corporate Development, which is associated with in-licensing and drug development pursuits. The Business Development group includes twenty sector experts with a huge knowledge in most aspects of drug advancement, including formulation, scientific operations, production and commercialization.

Paramount BioCapital Property Management

Property Management is responsible for acquiring and disseminating equities of global health care businesses. They have a proven hedge fund framework and property under management in various private positioning vehicles.

Paramount Purchasing Corporation

Paramount Acquisition Company makes distinctive private equity vehicles that match substantial capitals with late-stage non-public businesses. It recently announced a $54 million transaction with Valeritas, which is a medical device company having its key FDA-approved insulin pump h-Patch.

Paramount BioSciences Executive Management Team

On average, Paramount BioSciences personnel possess 15 years of strong working experience within the medical and regulatory functions. Headed by Lindsay Rosenwald, the associates took part in dozens of prescription advancement and commercialization assignments, including Rituxan, Viracept, Sutent, Kepivance, and Neulasta. More than fifty chemical substances currently undergo specialized medical development process and the products contain drug treatments throughout a broad selection of signs that include neurological diseases, metabolic problems, transmittable diseases and cancer.

Lindsay Rosenwald, M.D., is CEO and Chairman at Paramount BioSciences. His extensive working experience within biotechnology, pharmacology and finance made him one of the frontrunners in the biotechnology and life sciences industries. With more than twenty years of past experiences in developing and investing in biotechnology and life science companies, Dr. Lindsay Rosenwald set up and nurtured more than 40 biotech/pharma businesses.

J. Jay Lobell, J.D., is President and Chief Operating Officer at Paramount BioSciences. His previous knowledge includes partnership at Covington & Burling, where he supplied economic, regulatory, business, and litigation advice to financial organizations, firms and individuals.

Russell Ellison, m.d., is Executive Vice President with over 33 years of senior management experience in pharmaceutical advancement and marketing he is a former vice president clinical development at fibrogen, inc. and chief healthcare officer of sanofi-synthelabo, usa. Dr. Ellison additionally served as the us. Vice president of medical affairs and is a former we. Vice president, medical affairs and chief medical officer of Hoffman la ruche.

Advantages of Paramount BioSciences Style

Exactly what makes Paramount BioSciences a preferred acquirer of prescription drugs and developer of biotechnologies is that Lindsay Rosenwald’s development team along a world-wide corporate progression team that assesses and helps unit and market opportunities. The offices of Paramount BioSciences are located around the world, which includes New York City, London, Boston, Shanghai, San Diego, North Carolina, Orange County (California)). Promising drug candidates are shifted forward rapidly in the accreditation process. Reps of all areas in drug development cycle interact to make certain an understanding to move forward. The next phase is the generation of product development plans for the compound and hiring supervision personnel. At this stage, the substances are transferred to Portfolio Organizations with no transitional delay. The product candidates are supported throughout the specialized medical and regulatory procedure.

Paramount BioSciences has proved to rapidly perform offers and commence creation work. Its access to financing is an integral part of any product development. It provides Portfolio businesses with the construction that promotes drug candidate’s progression through to marketplace, getting rid of odds of program becoming stalled.

Medical and commercial expertise at the business stage assists Paramount Portfolio companies increase value to in-licensed items.

Background regarding Financial Wherewithal

Paramount BioSciences underneath the direction of Lindsay Rosenwald has produced over $1 billion from outside shareholders in addition to their own investment in Paramount’s portfolio companies. All organizations and medical research financed through the company get substantial financing on all levels of the creation cycle.

Linsay Rosenwald has normal and close interaction with the leading US sell-side and buy-side organizations that consist of notable medical care investors, with whom Paramount’s hedge funds invest in the deals not directly involving this company itself. Paramount’s personnel possess real-time knowledge of health care capital markets, which resulted in over $400 million funds for Portfolio Businesses in 2009 year alone, including $200 million by Paramount. This includes $47 million for Cougar Biosciences in conjunction with SG Cowen, $37 million for Ziopharm Oncology, $22 MM for Chelsea Therapeutics and $16 million for Innovive Pharmaceuticals. Many of the top health care funds borrowed in Paramount this year, which is always an excellent indication for the introduction of biotechnology and life sciences sectors.